Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...

Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently updated its clinical study titled A Phase 2, Multicenter, ...

APPLIN: After nearly 20 years in HIV care, I’ve seen that HIV follows people through every season of life. When life is stable, patients stay in care and maintain suppression, but when challenges ...

Leaders in HIV research highlighted the critical role of that research has played in advancing HIV science over the past 40 years. In a commentary in Nature Medicine, they explained how U.S.-funded ...

More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...

SINCE the 1980s, researchers have worked tirelessly to develop effective treatments that can suppress the HIV virus to ...

When diagnosed with HIV, the timing of treatment initiation can significantly impact long-term health outcomes and quality of life. Medical experts increasingly advocate for immediate treatment ...

Breast milk in women with HIV contains significantly lower levels of the essential amino acid tryptophan, researchers found. Tryptophan is important for an infant’s immune function, growth and brain ...

Some lawmakers and advocates are increasingly uncertain whether critical HIV and AIDS services will survive the federal government’s funding fight. The GOP’s House-passed budget bill seeks to cut over ...

More than 230 people became infected with HIV in Indiana, worsened by delayed action from former Gov. Mike Pence. Experts and ...

People living with HIV who smoke are currently more likely to die from lung cancer than from HIV-related causes. Two cancer ...